Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation.
about
Effector Functions of Natural Killer Cell Subsets in the Control of Hematological MalignanciesNatural killer cell biology: an update and future directionsNK cell therapy: targeting disease relapse after hematopoietic stem cell transplantationCommon Genetic Variants Found in HLA and KIR Immune Genes in Autism Spectrum DisorderDonors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantationGraft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies.Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease.Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection.Interaction between immunoglobulin allotypes and NK receptor genes in diabetes post-hepatitis C virus infectionNatural killer cell differentiation from hematopoietic stem cells: a comparative analysis of heparin- and stromal cell-supported methodsKIR diversity in three ethnic minority populations in China.Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.KIR repertory in patients with hematopoietic diseases and healthy family membersGenetics of graft-versus-host disease: the major histocompatibility complex.Killer Cell Immunoglobulin-Like Receptor-Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid LeukemiaEffect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantationKIR gene content diversity in four Iranian populations.IFN-γ stimulated human umbilical-tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro.What is the role for donor natural killer cells after nonmyeloablative conditioning?The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation.A Killer Immunoglobulin - Like Receptor Gene - Content Haplotype and A Cognate Human Leukocyte Antigen Ligand are Associated with Autism.The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT).Activating killer cell Ig-like receptors in health and disease.The role of natural killer cells in hematopoietic stem cell transplantation.Role of natural killer cells in hematopoietic stem cell transplantation: myth or reality?Use of NK cell activity in cure by transplant.Targeting natural killer cells and natural killer T cells in cancer.Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provision.Clinical utility of natural killer cells in cancer therapy and transplantation.Natural killer cell receptors: alterations and therapeutic targeting in malignancies.NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AMLComparing individual NK cell activity in vitro.The effect of missing KIR ligands, activating KIR genotype and haplotype on the outcome of T-cell-replete hematopoietic stem cell transplantation from HLA-identical siblings in Thai patients.KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals.Use of natural killer cells as immunotherapy for leukaemia.A significant effect of the killer cell immunoglobulin-like receptor ligand human leucocyte antigen-C on fibrosis progression in chronic C hepatitis with or without liver transplantation.Role of killer immunoglobulin-like receptor and ligand matching in donor selection.
P2860
Q26776538-B17A1DF0-BB17-45B1-A7C3-C46265C535FBQ26830512-ED8F1A4B-DDFE-4902-B354-953E20938345Q26863559-829620C7-9E29-43D6-84A7-742AC3EB8070Q28066081-9552A3BA-A9B0-494F-AA51-0DC493DFAB16Q33378868-5A444224-AF5D-4FBB-A480-C4E8562E26E3Q33765556-2147E0BA-E38E-41F4-85F7-3BFB0F571CCFQ33770125-E82CB8BE-53DC-4E36-983B-A91167676259Q33777096-8D95ADC2-47B6-4E64-ABC1-CF169B286242Q34193507-D39E1569-AF9A-4FD5-ADD1-39FD3C9D8794Q34615804-10A499FF-D8CE-4172-854E-053DEE306584Q34804539-4A5E47ED-C0B8-49C9-A11A-A674E7AF143FQ34949587-A8FC0B5D-6602-49BA-B47F-6E31EBE8EA23Q35830835-A7225619-70C3-4FA4-87C5-DDF0BC8FDC84Q35838483-33BC8B91-27E7-444B-885C-B5FA0A02A3ADQ36061068-F1FB2B51-A242-4D9E-9F5F-BC3D6E05F153Q36154501-AC9A7D26-E417-453A-AD7C-E3358CB2E7A6Q36766250-BDACAD88-6BBB-42AB-88A1-9FB782D0E8FEQ37024340-1F04FA42-E39A-4DFA-B1F9-DD5A76B0CEE8Q37227672-2D0221D2-E1D1-427D-BC9A-EE0DF7A257D7Q37252058-68C335C1-B1F8-4C02-B332-BF00B9BC4C89Q37299784-5CCF7796-3265-4E22-A5DA-A2A1DE1C35D0Q37327327-DFF21071-33A4-45AD-8F5F-C38C417383D2Q37405194-4878929E-23BB-411A-871A-295B00D8A138Q37413062-CBFC4B3B-C806-480F-B4F3-82E4DB657D00Q37589671-51CB9630-D1DD-4358-A444-A96A3AD18438Q37725657-7DD427DA-1CF7-4B3C-8B5F-5D69BF45827CQ37853569-56FB4359-B662-4EBB-AE8B-E422DCACA300Q37853787-CDA36C3B-0FD0-4CAC-94B7-96ED941E9F06Q37910960-FAF7F352-338B-4689-A4A2-93859172D633Q37995950-C93BA37E-2B22-46F8-B037-CE80A2A746DEQ38000901-E18618CF-905A-4121-A268-0B1BE65F84C4Q38195120-D1B639D5-2926-4CB6-955B-795912B2483EQ38587627-37F7B85B-0E44-41A7-AC69-A9563687D9E5Q38847073-114DD6C6-AC04-4000-A880-745BC248D8C1Q39197789-24FD2502-EA58-4B2E-8D41-BFCFF7CBE536Q39702233-7863A3D1-95C6-45CC-BB4F-8716C27AECE8Q40007789-8D01DB9A-95FB-4561-AE04-4BE769D3C242Q40047650-96AB914B-1F0A-4551-BBC7-0FF654125573Q40851782-3400E68E-B9D2-4E8C-9C07-48384106BB48Q41618466-926896A5-B302-4529-964C-C3F8A9A09CA4
P2860
Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Donor-recipient combinations o ...... opoietic cell transplantation.
@ast
Donor-recipient combinations o ...... opoietic cell transplantation.
@en
type
label
Donor-recipient combinations o ...... opoietic cell transplantation.
@ast
Donor-recipient combinations o ...... opoietic cell transplantation.
@en
prefLabel
Donor-recipient combinations o ...... opoietic cell transplantation.
@ast
Donor-recipient combinations o ...... opoietic cell transplantation.
@en
P2093
P2860
P1433
P1476
Donor-recipient combinations o ...... opoietic cell transplantation.
@en
P2093
Bharati Sanjanwala
Karina L McQueen
Kristel M Dorighi
Lisbeth A Guethlein
Peter Parham
P2860
P304
P356
10.1016/J.HUMIMM.2007.01.019
P577
2007-03-12T00:00:00Z